Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
B&G Foods Q1 2026 Earnings Call - Dividend Slashed 50% to Fund Debt Paydown Amid Portfolio Overhaul
B&G Foods is executing a rapid portfolio transformation, divesting the low-margin Green Giant U.S. Frozen business and acquiring the higher-margin College Inn and Kitchen Basics broth brands. The stra...
- B&G Foods completed the divestiture of its Green Giant U.S. Frozen business to Seneca Foods and acquired the College Inn and Kitchen Basics broth brands from Del Monte Foods, signaling a strategic shift toward higher-margin, shelf-stable categories.
- The dividend was cut by 50% to $0.095 per quarter, freeing up approximately $30 million annually to accelerate debt reduction and lower the net leverage ratio toward a target of below 5 times.
- Base business net sales grew 2.8% year-over-year in Q1 2026, reversing prior destocking trends and demonstrating resilience despite broader consumer softness in tracked retail channels.
- +7 more takeaways
Digimarc Q1 2026 Earnings Call - Gift Card Rollout Delays Offset by Strong Retail Momentum and AI Trust Strategy
Digimarc navigated a tricky Q1 2026, posting a 9% sequential ARR growth and a 400 basis point expansion in subscription gross margin, yet the top line took a hit from the loss of two legacy contracts....
- Ending ARR reached $15 million, up 9% sequentially, though it remains down 25% year-over-year due to the loss of two legacy contracts.
- The company secured its first commercial order for its secure gift card solution, generating over $500,000 in ARR from six closed-loop and open-loop brands.
- Rollout plans have advanced with 15 North American retailers, including 8 of the 20 largest by sales, up significantly from just two months ago.
- +9 more takeaways
Parks! America Q2 FY2026 Earnings Call - Macro Headwinds Hit March, but Core Operations Remain Resilient
Parks! America delivered mixed results for its second quarter of fiscal 2026, with strong January and February sales entirely offset by a sharp March downturn driven by macroeconomic headwinds. CEO Ge...
- Sales growth in Q2 FY2026 was driven entirely by January and February, with March showing a sharp decline as the peak season began.
- Rising gas prices and macroeconomic pressure on the ~$50,000-average-household demographic have created significant headwinds for discretionary spending.
- The company’s core customer base is rural and lower-income, making it highly sensitive to inflation in travel and fuel costs.
- +7 more takeaways
Intellicheck Q1 2026 Earnings Call - Fraud-Proof Growth Driven by Banking Vertical Amid Macro Headwinds
Intellicheck delivered a resilient Q1 2026 performance, posting 13% year-over-year revenue growth to $5.5 million and achieving positive adjusted EBITDA for the fourth consecutive quarter. The company...
- Revenue grew 13% year-over-year to $5.52 million, driven by strong performance in the banking and lending vertical, which now accounts for over 50% of total revenue.
- Adjusted EBITDA reached $935,000, marking the fourth consecutive quarter of positive adjusted EBITDA and a significant turnaround from a $17,000 loss in Q1 2025.
- GAAP net income was $636,000 ($0.03 per diluted share), representing the third consecutive quarter of profitability and a nearly $1 million year-over-year improvement.
- +7 more takeaways
IZEA Q1 2026 Earnings Call - Enterprise Pivot Delivers $18.9M Profit Swing Despite Revenue Decline
IZEA completed its deliberate exit from low-margin SMB work to focus exclusively on enterprise clients, a strategic reset that generated an $18.9 million net profit swing in 2025. While Q1 2026 revenu...
- Strategic Pivot Complete: IZEA finished its exit from the SMB segment, transitioning fully to an enterprise-focused model. This reset resulted in a massive $18.9 million net profit swing in 2025 and increased average revenue per account by 33%.
- Revenue Decline Due to Transition: Q1 2026 revenue fell to $6.6 million from $8.0 million in the prior year. Management attributes this entirely to the runoff of non-core SMB business and timing delays with enterprise accounts, not a loss of demand.
- Enterprise Growth Outpacing Market: Despite the revenue dip, IZEA's enterprise portfolio has grown at a healthy double-digit rate over the last 12 months, surpassing overall industry growth. New wins include Hulu, ASICS, and Garanimals.
- +7 more takeaways
TELA Bio Q1 2026 Earnings Call - Fully Resorbable Hernia Portfolio Launches Amid European Surge and Board Refresh
TELA Bio reported a modest 3% revenue increase to $19.1 million in Q1 2026, but the underlying commercial engine is shifting gears. The company launched OviTex LTR, a fully resorbable reinforcement po...
- TELA Bio reported Q1 2026 revenue of $19.1 million, a 3% increase year-over-year, with OviTex revenue at $12.6 million and international sales up 41% to $3.7 million.
- The company launched OviTex LTR, a fully resorbable tissue-based hernia repair portfolio, priced comparably to existing products to capture surgeons seeking alternatives to permanent synthetic meshes.
- U.S. commercial operations are now fully staffed with over 90 territory managers, including 19 new greenfield territories, shifting focus from hiring to execution and density.
- +7 more takeaways
Atea Pharmaceuticals Q1 2026 Earnings Call - HCV Phase III Enrollment Nears Completion, HEV Program Advances
Atea Pharmaceuticals reported a strong Q1 2026, driven by near-complete enrollment in its global HCV Phase III trials and progress on a new HEV program. The company has $256 million in cash, securing ...
- HCV Phase III Enrollment Milestones: C-BEYOND (North America) is fully enrolled with over 880 patients, while C-FORWARD (global) is 95% enrolled, with top-line data expected mid-year and year-end respectively.
- Strong Financial Position: Atea holds $256 million in cash and marketable securities as of March 31, 2026, extending its cash runway through 2027 to fund ongoing HCV and HEV programs.
- HEV Program Advancement: AT-587, a first-in-class direct-acting antiviral for chronic hepatitis E, has completed CTA-enabling studies and is on track for a first-in-human study mid-year, targeting a $750M-$1B annual market.
- +7 more takeaways
5E Advanced Materials Q3 FY2026 Earnings Call - Secures First Offtake Agreement, Advances High-Value Boron Products
5E Advanced Materials delivered a pivotal third quarter for fiscal 2026, marking its first major commercial milestone with a long-term offtake heads agreement for 7,500 tons of boric acid annually, wi...
- Secured first offtake heads agreement for 7,500 tons of boric acid annually, with optionality to increase to 10,000 tons, featuring fixed pricing, annual escalation, and a five-year term with automatic renewal.
- CEO Paul Weibel highlighted a successful customer roadshow in March, meeting with 12 end users and distributors, revealing strong domestic urgency for a resilient, reliable boron supply chain.
- Developed stable, free-flowing metaboric acid with approximately 80% B2O3 equivalent content, positioning 5E to capture higher margins between standard boric acid and boron oxide.
- +7 more takeaways
Evolv Technologies Q1 2026 Earnings Call - Raised 2026 Revenue Outlook on Purchase Subscription Mix and eXpedite Traction
Evolv Technologies delivered a strong first quarter, with revenue jumping 45% year-over-year to $46.3 million, driven by a shift toward purchase subscriptions that front-load product revenue and a rec...
- Revenue surged 45% year-over-year to $46.3 million, beating prior guidance and reflecting strong end-market demand.
- Annual recurring revenue (ARR) grew 20% to $127.3 million, signaling durable subscription momentum.
- Adjusted EBITDA margin expanded to 8.5% from 6.4% in the prior year period, despite gross margin compression from a fulfillment model shift.
- +7 more takeaways
OptimizeRx Q1 2026 Earnings Call - Revenue Guidance Cut Amid MFN Headwinds, But AI and Programmatic DSP Integration Offer Long-Term Upside
OptimizeRx delivered a solid Q1 2026, beating consensus on the top and bottom line, but management cut full-year revenue guidance to $95M-$100M due to short-term disruptions from Most Favored Nation (...
- Revenue Guidance Cut: Full-year 2026 revenue guidance lowered to $95M-$100M due to MFN-related disruption and cautious pharma budgeting, though adjusted EBITDA guidance of $21M-$25M is maintained.
- Q1 Results Beat Consensus: Q1 revenue was $19.8M (-10% YoY) but adjusted EBITDA rose 120% to $3.3M, beating estimates. Non-GAAP net income doubled to $2.7M.
- MFN Headwinds Persist: Contracted revenue remains 15-20% behind prior year levels, primarily driven by shorter contract durations as pharma clients react to Most Favored Nation pricing dynamics.
- +9 more takeaways